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1. Introduction
Osteoarthritis (OA) is a progressive degenerative joint disease that has a major impact on joint
function and quality of life. OA is a painful condition caused by a gradual loss of cartilage from
the joints and, in some people, joint inflammation [1]. Pain, stiffness, and difficulty moving the
joint easily are common symptoms of OA. Non-drug treatments for osteoarthritis have gained
popularity according to the American College of Rheumatology (ACR) [2] and can often reduce
the symptoms. Therefore, there is a significant need to improve current osteoarthritis therapies
and to search for novel therapies. Nutraceuticals and dietary supplements derived from herbs
have long been used in traditional medicine. Though they aren’t recognized as drugs, herbal
and natural remedies are used for a drug-like effect, and they can potentially cause the same
reactions and complications prescription drugs can cause. There is considerable evidence that
nutraceuticals may play an important role in inflammation and joint destruction in OA. The
World Health Organization (WHO) [3] has taken an interest in the indigenous system of
medicine; particularly, plant remedies. Ginger is widely used as a spice, an antiemetic and
carminative agent, and for its essential oils. Gingerols, in particular 6-gingerol, are the active
components of ginger. Proposed mechanisms include direct stimulation of the gastro-
intestinal tract, or serotonin antagonism in the gut or central nervous system [4, 5]. A study on
6-gingerol was shown to significantly inhibit the production of nitric oxide, a highly reactive
nitrogen molecule that quickly forms a very damaging free radical called peroxynitrite and
greatly lessened depletion of glutathione [6]. Other reports suggest that ginger produces its
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anti-inflammatory effect by inhibiting arachidonic acid metabolism [4, 7], induce apoptosis in
HL-60 leukemia [8], non-small cell lung cancer cells [9] and against acute monocytic leukemia
[10]. It is also reported to be chemopreventive and anti-inflammatory [11, 12]. The antioxidant,
antimicrobial and cytotoxic activities of Zingiber officinale displayed specific inhibition on
Escherichia coli was also studied [13]. Gingerols also promoted significant reduction in mRNA
transcription of TNF-α, IL-2 and INF-γ [14]. Ginsenoside Rg5 (Rg5), an abundant natural
compound in Panax ginseng, has been found to be beneficial in treating AD [15]. Pharmaco‐
logic studies in the last decades have shown that ginsenosides (ginseng saponins) are primarily
responsible for the actions of ginseng [16]. In diabetes ginger supplementation in oral admin‐
istration reduced inflammation in type 2 diabetic patients [17]. Other studies have shown that
ginger may benefits musculoskeletal disorder treatment [18] nausea and vomiting [19],
inflammation or inflammatory states [20, 21] such as osteoarthritis [20-22], migraine [23],
cancer [24], hyperlipidemia and hyperglycemia [25, 26]. In vitro studies suggest that ginger
produces its anti-inflammatory effect by inhibiting arachidonic acid metabolism4, 7. This
chapter intends to give a brief outline of ginger health benefit and to investigate the ability of
ginger tablets to reduce postoperative pain in patients with osteoarthritis.
1.1. History
The earliest evidence of humans' use of plants for healing dates back to the Neanderthal period
[27]. In the 16th century, botanical gardens were created to grow medicinal plants for medical
schools [28]. Herbal medicine practice flourished until the 17th century when more "scientific"
pharmacological remedies were favoured [29]. The use of plants for healing purposes predates
human history and forms the origin of much modern medicine. Many conventional drugs
originate from plant sources: a century ago, most of the few effective drugs were plant based.
Examples include aspirin (from willow bark), digoxin (from foxglove), quinine (from cinchona
bark), and morphine (from the opium poppy). The development of drugs from plants contin‐
ues, with drug companies engaged in large scale pharmacological screening of herbs.
1.2. Therapeutic scope
Although herbal preparations are widely used as self-medication for acute conditions,
practitioners of herbal medicine tend to concentrate on treating chronic conditions. A typical
caseload might include asthma, eczema, premenstrual syndrome, rheumatoid arthritis,
migraine, menopausal symptoms, chronic fatigue, irritable bowel syndrome and lately to treat
mental or musculoskeletal disorders.
1.3. Safety
Many plants are highly toxic. Herbal medicine probably presents a greater risk of adverse
effects and interactions than any other complementary therapy. There are case reports of
serious adverse events after administration of herbal products. In most cases the herbs
involved were self-prescribed and bought over the counter or obtained from a source other
than a registered practitioner. In the most notorious instance, several women developed
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rapidly progressive interstitial renal fibrosis after taking Chinese herbs prescribed by a
slimming clinic
2. Method and subjects
2.1. Method
Fourthly patients with OA of the knee and moderate-to-severe pain were enrolled in a
randomised, double –blind, placebo-controlled, two-center, parallel group, 12-week study.
The primary efficacy variable was the proportion of responders experiencing a reduction in
“knee pain on standing” using a visual analog scale.
The study was approved by the ethics committee of the Latvian Institute of Cardiology for
clinical and physiological research, drug and pharmaceutics product clinical investigation.
Only those willing to participate and after getting their informed consent will be involved in
the investigation
2.2. Subjects
Elderly patients with clinical diagnosis of osteoarthritis (OA) of the knee, defined as knee
(articular and not periarticular or referred) pain for most days of the prior month and radio‐
graphic osteophytes at the tibiofemoral joint margins were involved in the study. All involved
patients had a baseline pain score > 40 mm and < 90 mm on a 100-mm Visual Analogue Scale
(VAS) at the time of randomization, when evaluating pain on standing during the last 24 hours.
Both men and women were included.
Exclusion Characteristics
• No NSAID's or other medication before intervention start-or consider including one week
wash-out period.
• History of allergy to ginger;
• History of rheumatoid disease;
• History of asthma, if the patient needs treatment with steroids;
• Treatment with oral corticosteroids within four weeks prior to screening;
• Treatment with intra-articular corticosteroids;
• Treatment with intra-articular hyaluronic acid within 6 months prior screening;
• Prior treatment with immuno-suppressive drugs, cytostatic drugs, gold or peniciilamine;
• Other investigational drugs within one month prior to screening;
• History or clinical signs of impaired kidney function;
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• Clinical signs of liver disorders;
• Severe neurological diseases;
• Increased oral temperature, (37,5 C) at the time of screening;
• Affection of the hip to an extent that would influence the ratings done at the visits";
• History of fibromyalgia;
• Gout;
• Recurrent or active pseudo-gout;
2.2.1. Study design
The study was 12 weeks, double blind, and placebo-controlled, parallel group trial performed
in two social care centres for elderly people. The study was approved by the ethics committee
of the Latvian Institute of Cardiology for clinical and physiological research, drug and
pharmaceutics product clinical investigation. Only those willing to participate and after
getting their informed consent will be involved in the investigation. Patients were randomised
to receive treatment and both investigators and the patients were blind to treatment assign‐
ment.
2.2.2. Treatment
During the 12-week period, patients ingested 1 capsule twice daily, morning and evening. Each
capsule contained 150 mg Ginger rhizome (lat. Zingiberis officinale rhizome) powdered extract
and 125 mg Galangae rhizome (Alpinia officinarum rhizome) dry extract. 22 patients were got
tablets with “A” and 18 patients got tablets with “B”. Examination was done at the baseline,
after 6 weeks and after 12 weeks.
2.2.3. Results
Characteristics of the subjects
Forty patients were included in the study (for group “A”-mean age ± SD 69±13,7 and for group
“B”-mean age ± SD 75 ± 8,6). There were ten males (35 %) and thirty females (75%). The patients
in both groups were generally overweight, since the average was >28 kg/m2 (range 43 – 120
kg).
2.2.4. Assessments
The primary efficacy parameter was proportion of respondents experiencing at least a 15-mm
reduction in pain between baseline and the final examination for knee pain on standing and
walking during preceding 24 hours, as measured by a 100-mm, VAS.
The secondary measurement was mean ±SE of measurements for knee pain on standing and
walking.
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Baseline data After 6 weeks after 12 weeks
A B A B A B
n=22 n=18 n=20 n=18 n=20 n=18
Pain on standing and
walking (%)
> 15 mm - - - - 50 44
0 – 15 mm - - - - 41 50
≤ 0 - - - - 9 6
Pain on standing, mean
± SE (mm) 62.95±2.2 57.11±+2.5 56.65±2.3 49.52±2.5 51.2±2.3 43.88±2.5
Pain on walking, mean
± SE (mm) 61.68±2.4 60.64±2.7 54.85±2.5 54±2.7 49.25±2.5 49.23±2.7
Table 2. Measurements for knee pain between group “A” and group “B”
-10
0
10
20
30
40
50
60
70
More than 15mm 0 - 15 mm Negative result
%
A
B
Figure 1. Pain on standing and walking after using of Ginger containg food supplements
” A” group (n=22) “B “group (n=18)
Age, mean ± SD years 69 ± 13,7 75 ± 8,6
Sex %
Men 23 28
Women 77 72
Body mass index ± SD kg/m2 29.31 ± 7,7 28 ± 7,0
Waste/hip ratio ± SD 0,88 ± 0,04 0,91 ± 0,04
Table 1. Demographic characteristics
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Figure 2. Knee pain on standing as measured by 100-mm visual analog scale at baseline and after 6 weeks and 12
weeks. Bars shows means with 2 SE (mm)
Additionally blood sample was checked in both groups. There were no statistically significant
changes between groups.
Baseline data After 12 weeks
A B A B
n=22 n=18 n=20 n=18
Erytrocytes, Mean±SE, (10
[12]/L) 4.42±0.9 4.46±1 4.31±0,09 4.2±1
Hb Mean±SE, (g/L) 131.66±5.8 135.8±6.5 134.8+5.9 113.15±6.5
Hematocrit Mean±SE (%) 39.28±0.9 40.03±1.0 38.8±0.9 37.85±1.0
WBC Mean±SE (109/L) 7.7±0.5 6.4±0.5 6.38±0.5 5.6±0.5
ESR Mean±SE (mm/h) 23.77±3.6 20.06±4.0 19.31±3.8 18.76±4.1
Table 3. Comparison of blood samples between both groups in the study.
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3. Discussion and conclusion
Ginger (Zingiber officinale Roscoe), a well-known spice plant, has been used traditionally in
a wide variety of ailments including hypertension and osteoarthritis. Gingerol, the active
components of ginger, derivatives are currently under investigation as potential drug therapy
for disorders of platelet function, but the small amounts consumed in the diet are unlikely to
influence platelet function. We report here the osteoarthritis effects of Zingiber officinale and
Alpinia galanga tablets under controlled experimental conditions.
Osteoarthritis, the most common form of arthritis, is a debilitating progressive disease
principally affecting the elderly. Osteoarthritis therapy has evolved in the past few decades
from symptomatic treatment to possible disease-modifying solutions. Osteoarthritis continues
to be a difficult disorder to treat, as there is no cure as such and current treatments focus mainly
on relieving pain and maintaining joint function. The search nevertheless continues for
management regimens that can slow, alter or reverse the degenerative processes of osteoar‐
thritis. Experimental therapies that seek to modify the course of osteoarthritis. These include
such medications as colchicine, bisphosphonates and hormones. Dietary therapeutics, such as
ginger extract also has been suggested. Current approaches to treating osteoarthritis-i.e.
medications; nonpharmacological modalities, such as physical therapy, exercise, weight
management and orthotics; and (as a last resort) surgery-focus on reducing pain and improv‐
ing (or at least maintaining) mobility
Musculoskeletal conditions are prevalent and their impact is pervasive. They are the most
common cause of severe long-term pain and physical disability. The prevalence of many of
these conditions increases markedly with age, and many are affected by lifestyle factors, such
as obesity and lack of physical activity. The increasing number of older people and the changes
in lifestyle throughout the world mean that the burden on people and society will increase
dramatically. This has been recognized by the United Nations and WHO, with their endorse‐
ment of Bone and Joint Decade 2000–2010 [30]. Osteoarthritis was estimated to be the eighth
leading non-fatal burden of disease in the world in 1990, accounting for 2.8% of total years of
living with disability, around the same percentage as schizophrenia and congenital anomalies
[31]. It was the sixth leading cause of years of living with disability at the global level, ac‐
counting for 3% of the total global years of living with disability [32], [33], [34]. According to
the American Holistic Medical Association it is believed that the spiritual element should also
be taken into account when assessing a person's overall well-being [35], [36]. Ginger is an herb
which has been used for centuries in Ayurdevic medicine to relieve the pain of arthritis
although few studies are available to demonstrate its benefits. There appears to be good
evidence from epidemiological studies and clinical trials that Zingiber officinale and Alpinia
galanga tablets lower osteoarthritis tendency. The mechanism of action is believed to be due
to the inhibition of prostaglandin and leukotriene synthesis. Zingiber officinale and Alpinia
galanga was also tested for antibacterial activities by evaluating growth delays using human
strains of the genera Staphylococcus and Micrococcus. Staphylococcus aureus was found to
be sensitive to the ginger extract. When the extract was tested for the haemolytic effect, no lytic
effects on procaryotic cells were found. Patients suffering from such disorders reported relief
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in pain and associated symptoms on extract administration. No significant side effects of
supplementation were noted, which may be considered as adjuvant therapy in patients with
osteoarthritis of the knee. In this study ginger extract may have a beneficial effective in
treatment for osteoarthritis. However, more observational studies, with a larger sample size,
are needed to confirm the encouraging preliminary data on effectiveness and safety. The use
of Zingiber officinale and Alpinia galanga in osteoarthritis will reduce the symptoms to an
equivalent extent in elderly people with osteoarthritis.
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